D
Design Therapeutics, Inc. (DSGN)
NMS – Real vaqt narxi. Valyuta: USD
15.79
+0.18 (1.15%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
15.79
+0.18 (1.15%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Design Therapeutics, Inc. — bu genetik kasalliklarni davolash uchun kichik molekulali terapevtik dorilarni tadqiq qiluvchi, ishlab chiquvchi va tijoratlashtiruvchi klinik bosqichdagi biofarmatsevtika kompaniyasidir. Kompaniya irsiy kasalliklar uchun terapevtik nomzodlarni ishlab chiqish va rivojlantirish uchun GeneTAC platformasidan foydalanadi. Ushbu kasalliklar nukleotid takroriy kengayishi natijasida yuzaga keladi. Potensial kasallikni o'zgartiruvchi davolash uchun uning etakchi mahsulot nomzodlari quyidagilarni o'z ichiga oladi: Friedreich ataksiyasi - bu mitoxondrial funksiyaga bog'liq bo'lgan organ tizimlariga ta'sir qiluvchi, nevrologik, yurak va metabolik disfunksiyaga olib keladigan monogen, avtosomal retsessiv, progressiv multisistem kasallik; miyotonik distrofiya turi-1 - skelet mushaklari, yurak, miya va boshqa organlarga ta'sir qiluvchi dominant irsiylangan, monogen progressiv nevromuskulyar kasallik; Fuchs endotelial korneal distrofiyasi - bu ko'zning ikki tomonlama endotelial hujayralarining degeneratsiyasi va progressiv ko'rish qobiliyatining yo'qolishi bilan tavsiflangan genetik ko'z kasalligi; va Xantingon kasalligi - bu harakat, kognitiv va psixiatrik buzilishlar bilan tavsiflangan dominant irsiylangan, monogen neyrodegenerativ kasallik. Kompaniya 2017-yilda tashkil etilgan va Kaliforniyaning Karlsbadd shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Aseem Z. Ansari Ph.D. | Co-Founder & Scientific Advisor |
| Dr. Chengzhi Zhang Ph.D. | Chief Chemist |
| Dr. Chris M. Storgard M.D. | Chief Medical Officer |
| Dr. Sean Jeffries Ph.D. | Chief Operating Officer |
| Dr. Tadimeti S. Rao Ph.D. | Chief Scientific Officer |
| Mr. Doane Chilcoat Ph.D. | Chief Technology Officer |
| Mr. Jim Kerr | Chief of Manufacturing & Product Development |
| Mr. Mustapha Parekh | General Counsel |
| Mr. Pratik Shah Ph.D. | Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson |
| Ms. Julie D. Burgess CPA | Chief Accounting Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-28 | 8-K | dsgn-20260428.htm |
| 2026-04-28 | 10-Q | dsgn-20260331.htm |
| 2026-04-23 | DEFA14A | dsgn-defa14a-2026.htm |
| 2026-04-01 | 8-K | dsgn-20260331.htm |
| 2026-03-09 | 8-K | dsgn-20260309.htm |
| 2026-01-30 | 8-K | d14213d8k.htm |
| 2025-11-05 | 8-K | dsgn-20251105.htm |
| 2025-11-05 | 10-Q | dsgn-20250930.htm |
| 2025-09-10 | 8-K | dsgn-20250909.htm |
| 2025-08-07 | 10-Q | dsgn-20250630.htm |